drugset / Trial / NCT04827719
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy
Timeline
- Start
- 2021-05-01
- Primary completion
- 2025-01-13
- Completion
- 2025-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aspacytarabine | Small molecule | 2.3 g | Intravenous |
| Subject | aspacytarabine | Small molecule | 4.5 g | Intravenous |